Felipe Heemann

Prof. Felipe Heemann

University of São Paulo, Ribeirão Prêto, São Paulo, Brazil
orcid
Open to non-Cartesian reviews and discussions

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
Felipe HeemannFelipe Heemann
Felipe Heemann
The 2013 removal of Aspergerʼs syndrome from DSM-5 was defended on evidential grounds that were, at the level of measurement, sound: inter-rater reliability for the distinction was poor, and symptom distributions across the autism spectrum are continuous. From these fndings the field drew a further conclusion, that no distinct This paper examines the step from the frst claim to the second and argues that it does not follow. The inference requires an unstated identity criterion, namely that a psychiatric kind, if real, must appear as a bounded region in a space of additive symptom coordinates. That criterion is not entailed by the data; it is a methodological commitment, and it is demonstrably inadequate to systems whose identity is carried by the structure of their dynamics rather than by the values of their variables at a moment. The paper does not claim that questions posed in symptom space are meaningless: they are intelligible and have answers, and the continuity fndings are those answers. It claims something narrower and defensible: that a negative answer at the symptom level licenses no conclusion at the dynamical level. On that basis I propose a candidate intra-spectrum kind, named here conative hormophoria, specified not by symptom counts but by a four-family dynamical fingerprint (long-range temporal correlations, functional excitation–inhibition ratio, neuronal avalanche statistics, and the dynamics of metastable connectivity). The construct is advanced as a hypothesis, not a kinding, and is deliberately constructed to be orthogonal to ability level and support needs, a stipulation that makes it refutable in a specific and consequential way.

12 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Felipe HeemannFelipe Heemann
Felipe Heemann
Synthetic cannabinoids (SCs), marketed as Spice, K2, and dozens of successor compounds, constitute one of the most pharmacologically dangerous categories of new psychoactive substances (NPS) currently in circulation. Their extreme toxicity relative to Δ9-tetrahydrocannabinol (THC) cannot be explained by CB1 receptor pharmacokinetics alone. This review proposes that the purinergic signaling system, specifically the P2X7 receptor and the adenosine receptor heteromers A2A–D2 and A1–D1, constitutes the central molecular amplifier of SC-induced neurotoxicity, operating downstream of CB1 superagonism but upstream of the neurological phenotypes that define acute SC poisoning. Full CB1 agonism collapses retrograde synaptic suppression, unleashing glutamatergic excitotoxicity and mitochondrial dysfunction that release massive quantities of extracellular ATP as a damage-associated molecular pattern (DAMP). P2X7, acting as the primary cellular sensor of this ATP surge, initiates NLRP3 inflammasome assembly, caspase-1 activation, and IL-1β secretion, establishing a self-sustaining neuroinflammatory cycle in the striatum and cortex. Simultaneously, the ectonucleotidase-mediated conversion of excess ATP to adenosine floods A2A receptors on striatopallidal neurons, allosterically reducing D2 receptor affinity for dopamine through the constitutive A2A–D2 heterodimer — directly suppressing dopaminergic motor tone and contributing to the psychomotor arrest clinically described as the zombie effect. The A1–D1 heteromer in the direct pathway adds a complementary layer of inhibition. Together, these purinergic–dopaminergic molecular interactions translate CB1 superagonism into the distinctive and dangerous clinical phenomenology of SC intoxication in ways that classical cannabinoid pharmacology does not predict. Pharmacological implications include the potential repositioning of P2X7 antagonists and A2A receptor antagonists as interventions for acute SC poisoning, and the necessity of integrating purinergic endpoints into toxicological profiling of emerging NPS compounds.

8 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
Felipe HeemannFelipe Heemann
Felipe Heemann
Medicine is the last natural science to conduct its reasoning under a geometry it has never examined. The clinic computes on a Cartesian-Laplacian substrate-linear, deterministic, organized around the average and the discrete category-and applies that substrate to an organ whose dynamics are nonlinear, recurrent, and fractal. The mismatch is not a measurement error to be corrected by better instruments. It is a category error in the precise sense Wittgenstein gave to grammatical confusion: the instrument and the object belong to incommensurable geometric regimes, and the output of their forced encounter is not an approximation but a malformed question. This essay argues that the diagnostic categories of psychiatry, the behavioral nosology formalized in 1980 and unrevised in its logic since, are the most visible instance of this anachronism, and that the field already possesses, in its own published literature, every conceptual instrument required to replace it: the network theory of psychopathology, the mathematics of critical transitions, the fractal physiology of the last three decades. What it lacks is not evidence. What it lacks is the courage to change geometries. The deeper diagnosis is that medicine, having mistaken the physiologism of the 18th century for rigor, has surrendered its independence as a science and survives as a scientific pragmatics-competent in applying frontier science it neither generated nor understands at the level of generative structure, propped on one side by biology and on the other by physics. To make the abstraction concrete I take a single case-the catecholaminergic substrate that the categories ADHD, anhedonic depression, bipolar II, cyclothymia, and Restless Legs Syndrome partition and scatter-and show that dopaminergic dysregulation is not the cause of these conditions but their shared low-dimensional symptom: the visible projection of a high-dimensional system fallen out of phase. The category did not survive because it was true. It survived because the apparatus that depends on it cannot yet imagine the geometry that would dissolve it.

22 April 2026
Verified
Preprint
Open access
Felipe HeemannFelipe Heemann
Felipe Heemann
Contemporary clinical medicine operates with an epistemic apparatus borrowed, largely unrevised, from 19th century inferential statistics and a Laplacian-Cartesian ontology that the systems it proposes to treat-living bodies, nervous systems, minds-have never obeyed. The randomized controlled trial is not questioned here as a method; it is questioned as a sovereign. Once a drug leaves the averaged patient of the phase-III curve and meets the single patient at the bedside, the tacit metaphysics of the trial collapses: diagnostic categories reveal themselves as soft thresholds on continuous distributions, mechanisms of action prove to be dose-reversing and history-dependent, and the system under intervention-functioning within a strictly non-linear regime-carries the memory of every molecule it has ever met. This essay argues that a mature molecular neuropsychopharmacology must rest on three simultaneous commitments. Epistemically, it must prioritize a non-Laplacian apparatus: one that deploys causal discovery, multivariable Mendelian randomization, and targeted maximum likelihood to dismantle the illusions of observational correlation, while integrating marginal structural models and Lyapunov analysis to map the divergent trajectories of a system where interindividual variability is signal, never noise. Pharmacologically, it must abandon the fiction of equilibrium binding and read receptor occupancy as a hysteretic, path-dependent adaptation: a continuous remapping of the system's topology where desensitization and differential expression are not noise, but the very language of its non-linear memory. Ontologically, it must break with the Cartesian pilot haunting psychiatric thought and relocate the site of drug action within the phenomenological corps-sujet. Here, consciousness is not a spectator to neural events but the embodied style in which a living body inhabits its world, a realization that the psychotropic effect is not an adjustment of a biological machine, but a topological shift in the patient's very horizon of possibility. Read through this triple commitment, psychotropics-from classical antipsychotics to psychedelics and cannabinoids-cease to be mere items in a therapeutic drawer and become probes into the very architecture of selfhood: chemical perturbations that reveal the fragile, non-linear topology of the mind they modulate. The clinician who emerges is no longer a herald of protocols but an architect of homeostasis, trained to decipher the pharmacological grammar of a molecule and navigate its complex translation into the unique, path-dependent trajectory of an individual life.

28 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
Felipe HeemannFelipe Heemann
Felipe Heemann
The neural architecture of arousal and wakefulness emerges from the coordinated activity of at least six chemically distinct neuromodulatory systems-histaminergic, cholinergic, noradrenergic, dopaminergic, serotonergic, and orexinergic-whose functional differentiation and mutual interdependence resist reduction to any single hierarchical command structure. Standard didactic approaches in neuropsychopharmacology frequently fragment this architecture into isolated neurotransmitter profiles, sacrificing integrative coherence for taxonomic convenience. The present article formalizes and extends the Chicken Coop Theory (CCT), a structured functional allegory originally developed within the Psychotropica Neuroscience framework, as a pedagogically and epistemically rigorous model for the integrated teaching of arousal neurobiology, state-space dynamics, and clinical psychopharmacology. Each allegorical role-Gatekeeper (histamine), Spotlight Operator (acetylcholine), Salience Marker (noradrenaline), Reward Evaluator (dopamine), Patience Keeper (serotonin), and State Stabilizer (orexin)-is grounded in mechanistic neuroanatomy, receptor pharmacology, and systems-level evidence. The model generates testable clinical predictions across six canonical pathological scenarios and provides a principled framework for pharmacological reasoning that aligns with the distributed, non-hierarchical nature of arousal regulation. We argue that the CCT constitutes not a simplification of consciousness architecture but a compressed formal map whose internal logic preserves the mechanistic topology of the system it represents-a distinction with direct consequences for how we train clinicians and design pharmacological interventions.

26 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
Felipe HeemannFelipe Heemann
Felipe Heemann
Contemporary clinical medicine operates with an epistemic apparatus borrowed, largely unrevised, from 19th century inferential statistics and a Laplacian-Cartesian ontology that the systems it proposes to treat-living bodies, nervous systems, minds-have never obeyed. The randomized controlled trial is not questioned here as a method; it is questioned as a sovereign. Once a drug leaves the averaged patient of the phase-III curve and meets the single patient at the bedside, the tacit metaphysics of the trial collapses: diagnostic categories reveal themselves as soft thresholds on continuous distributions, mechanisms of action prove to be dose-reversing and history-dependent, and the system under intervention-functioning within a strictly non-linear regime-carries the memory of every molecule it has ever met. This essay argues that a mature molecular neuropsychopharmacology must rest on three simultaneous commitments. Epistemically, it must prioritize a non-Laplacian apparatus: one that deploys causal discovery, multivariable Mendelian randomization, and targeted maximum likelihood to dismantle the illusions of observational correlation, while integrating marginal structural models and Lyapunov analysis to map the divergent trajectories of a system where interindividual variability is signal, never noise. Pharmacologically, it must abandon the fiction of equilibrium binding and read receptor occupancy as a hysteretic, path-dependent adaptation: a continuous remapping of the system's topology where desensitization and differential expression are not noise, but the very language of its non-linear memory. Ontologically, it must break with the Cartesian pilot haunting psychiatric thought and relocate the site of drug action within the phenomenological corps-sujet. Here, consciousness is not a spectator to neural events but the embodied style in which a living body inhabits its world, a realization that the psychotropic effect is not an adjustment of a biological machine, but a topological shift in the patient's very horizon of possibility. Read through this triple commitment, psychotropics-from classical antipsychotics to psychedelics and cannabinoids-cease to be mere items in a therapeutic drawer and become probes into the very architecture of selfhood: chemical perturbations that reveal the fragile, non-linear topology of the mind they modulate. The clinician who emerges is no longer a herald of protocols but an architect of homeostasis, trained to decipher the pharmacological grammar of a molecule and navigate its complex translation into the unique, path-dependent trajectory of an individual life.